TRi-1

• Description :

  TRi-1 is a potent, specific and irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Others

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/tri-1.html

• Concentration :

  10mM

• Purity :

  99.91

• Solubility :

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles :

  O=[N+](C1=CC=C(OC)N=C1S(=O)(C2=CC=C(Cl)C=C2)=O)[O-]

• Molecular Formula :

  C12H9ClN2O5S

• Molecular Weight :

  328.73

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Stafford WC, et al. Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018 Feb 14;10 (428) . pii: eaaf7444.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [246020-68-8]